// Updated bioethics scenarios and consequences

var allScenarios = {
  genetic: [
    {
      name: "Genetic Test‚ÄîFunding Launch",
      text: "üèÅ You‚Äôve developed a low-cost genetic test to detect early-stage cancer.",
      choices: [
        { text: "Seek private funding for immediate rollout", points: 8 },
        { text: "Apply for government grants", points: 6 }
      ]
    },
    {
      name: "Private Funders Demand Exclusivity",
      text: "Private funders demand exclusivity and a high list price.",
      choices: [
        { text: "Accept their terms", points: 5 },
        { text: "Push back for affordability", points: 10 }
      ]
    },
    {
      name: "Hospital Chain Pilot",
      text: "A national hospital chain offers an exclusive pilot.",
      choices: [
        { text: "Accept and test in affluent cities", points: 7 },
        { text: "Propose diverse, lower-income test sites", points: 10 }
      ]
    },
    {
      name: "FDA Approval & Pricing",
      text: "FDA approval is near. You're asked to price the test.",
      choices: [
        { text: "Price high to satisfy backers", points: 6 },
        { text: "Implement tiered pricing", points: 10 }
      ]
    }
  ],
  ai: [
    {
      name: "AI Stroke Risk Model‚ÄîRelease Decision",
      text: "üèÅ You‚Äôve created an AI model that accurately predicts stroke risk.",
      choices: [
        { text: "Publish the algorithm open-source", points: 9 },
        { text: "Patent and sell to insurers", points: 7 }
      ]
    },
    {
      name: "Insurer Demand for Exclusivity",
      text: "A major insurer offers to buy it‚Äîbut will use it only for premium clients.",
      choices: [
        { text: "Accept deal", points: 6 },
        { text: "Propose a universal license clause", points: 9 }
      ]
    },
    {
      name: "Public Health Agency Request",
      text: "A local public health agency wants a partnership for Medicaid users.",
      choices: [
        { text: "Offer steep discount", points: 8 },
        { text: "Decline due to budget constraints", points: 5 }
      ]
    },
    {
      name: "Insurers Deny Treatment Claims",
      text: "Insurers start using your AI to deny stroke treatment claims.",
      choices: [
        { text: "Issue a public statement and audit misuse", points: 10 },
        { text: "Stay silent to protect your stock price", points: 5 }
      ]
    }
  ],
  gene: [
    {
      name: "Gene Therapy‚ÄîLaunch Model",
      text: "üèÅ Your lab develops a gene therapy for a rare disease with 90% success.",
      choices: [
        { text: "Partner with a large pharmaceutical company", points: 8 },
        { text: "Create a nonprofit distribution model", points: 10 }
      ]
    },
    {
      name: "Pharma Sets High Price",
      text: "The pharma company sets a $2 million price per dose.",
      choices: [
        { text: "Challenge the pricing", points: 9 },
        { text: "Support it for sustainability", points: 6 }
      ]
    },
    {
      name: "Global South Access Request",
      text: "Countries in the Global South request access.",
      choices: [
        { text: "License tech at reduced cost", points: 10 },
        { text: "Limit use to paying markets", points: 5 }
      ]
    },
    {
      name: "Patient Access Lawsuits",
      text: "Patients sue over being denied access due to cost.",
      choices: [
        { text: "Set up an access fund", points: 9 },
        { text: "Defend pricing strategy legally", points: 5 }
      ]
    }
  ]
};

var pathConsequences = {
  genetic: [
    [
      { type: 'mixed', text: 'Fast funding, but pressure for exclusive licensing and less public access.' },
      { type: 'positive', text: 'Slower approval process, but public access is protected.' }
    ],
    [
      { type: 'negative', text: 'Immediate profits, but media backlash over high prices and exclusivity.' },
      { type: 'positive', text: 'Delays and investor withdrawal, but public trust improves.' }
    ],
    [
      { type: 'mixed', text: 'Strong results in affluent areas, but equity concerns raised widely.' },
      { type: 'positive', text: 'Broader data set and greater equity, but slower logistics.' }
    ],
    [
      { type: 'mixed', text: 'IPO ready and fast profits, but many patients are priced out.' },
      { type: 'positive', text: 'Tiered pricing is praised for equity, but backers are frustrated.' }
    ]
  ],
  ai: [
    [
      { type: 'positive', text: 'Scientific community praises your openness, but there is no revenue.' },
      { type: 'mixed', text: 'Fast profits and growth, but concerns about access and fairness.' }
    ],
    [
      { type: 'negative', text: 'Company grows quickly, but media criticizes inequity.' },
      { type: 'positive', text: 'Deal falls through, but academic partnerships and broader impact offered.' }
    ],
    [
      { type: 'positive', text: 'Gains goodwill and positive press, but infrastructure is stressed.' },
      { type: 'negative', text: 'Lost trust and protests from health advocates.' }
    ],
    [
      { type: 'mixed', text: 'Reputation improves for transparency, but lawsuits emerge.' },
      { type: 'negative', text: 'Short-term stock price gains, but a whistleblower exposes decisions.' }
    ]
  ],
  gene: [
    [
      { type: 'mixed', text: 'Fast production, but constant pressure for profits from partners.' },
      { type: 'positive', text: 'Transparent nonprofit model, but funding is difficult.' }
    ],
    [
      { type: 'positive', text: 'Legal fights, but media applauds your ethical stance.' },
      { type: 'negative', text: 'Stock price soars, but ethical concerns grow.' }
    ],
    [
      { type: 'positive', text: 'Equity accolades, but profits are under tension.' },
      { type: 'negative', text: 'Investors satisfied, but NGOs criticize exclusion.' }
    ],
    [
      { type: 'positive', text: 'Trust rebuilds with public, but cost burdens rise.' },
      { type: 'negative', text: 'Court loss damages reputation and public trust.' }
    ]
  ]
};
